SLC18A1
Chromaffin granule amine transporter
Protein Summary
Involved in the transport of biogenic monoamines, such as serotonin, from the cytoplasm into the secretory vesicles of neuroendocrine and endocrine cells. The vesicular monoamine transporter acts to accumulate cytosolic monoamines into vesicles, using the proton gradient maintained across the vesicular membrane. Its proper function is essential to the correct activity of the monoaminergic systems that have been implicated in several human neuropsychiatric disorders. The transporter is a site of action of important drugs, including reserpine and tetrabenazine (Peter et al., 1993 [PubMed 7905859]). See also SLC18A2 (MIM 193001).[supplied by OMIM, Mar 2008]
- ENST00000265808
- ENSP00000265808
- ENSG00000036565
- ENST00000276373
- ENSP00000276373
- ENST00000381608
- ENSP00000371021
- ENST00000437980
- ENSP00000413361
- ENST00000440926
- ENSP00000387549
- ENST00000519026
- ENSP00000429664
- VAT1
- VMAT1
- CGAT
- VAT1
- VMAT1
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
co-expressed gene | 0.98 | ||
PubMedID | 0.56 | ||
cell type or tissue | 0.5 | ||
chemical | 0.49 | ||
cellular component | 0.48 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 172.53 (req: < 5)
Gene RIFs: 26 (req: <= 3)
Antibodies: 148 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 172.53 (req: >= 5)
Gene RIFs: 26 (req: > 3)
Antibodies: 148 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 6
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 1
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 2